PPD Appoints Neil McCullough, Ph.D., Vice President of Quality Management Systems

PPD Appoints Neil McCullough, Ph.D., Vice President of Quality Management Systems

WILMINGTON, N.C. (August 25, 2010) - PPD, Inc. (Nasdaq: PPDI) today announced it has named Neil McCullough, Ph.D., as vice president of quality management systems. In this role, Dr. McCullough will provide strategic direction for quality management across all lines of business and ensure full compliance with global regulations guiding the biopharmaceutical industry.

"Providing superior quality services directly impacts our ability to meet and exceed client expectations for safety, compliance, integrity of data and efficiency," said David Grange, chief executive officer of PPD. "Having led quality assurance initiatives for pharmaceutical companies for more than 20 years, Dr. McCullough brings exceptional leadership skills and quality expertise that enhance our ability to deliver for clients in today's changing drug development environment."

Prior to joining PPD, Dr. McCullough spent nine years at Pfizer Inc. He most recently served as senior director of the global research and development division good clinical practice and good laboratory practice quality assurance leadership team. His responsibilities included designing and implementing a risk-based approach to quality assurance to target audits across all functional areas of global clinical development.

Prior to joining Pfizer, Dr. McCullough served as a consultant to GlaxoSmithKline's division of manufacturing, where he implemented standards, procedures and policies to meet regulatory requirements. He was also site technical director at Polychem Limited and began his career as a manufacturing quality assurance laboratory technician at Beecham Group Ltd.

Dr. McCullough earned his doctorate in chemistry from The University of Kent at Canterbury in the United Kingdom and is completing a master's in pharmaceutical medicine from Harvard University and the Royal College of Physicians in Ireland (Hibernia College).

PPD is a leading global contract research organization, celebrating 25 years of providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 41 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the above named employee's performance and contributions to PPD and its quality management services, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract, integrate and retain key personnel; rapid technological advances that make our products and services less competitive; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; risks associated with acquisitions and investments, such as impairments;  and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media:
Sue Ann Pentecost
+919 456 5890
[email protected]

Analysts/Investors:
Luke Heagle
+910 558 7585
[email protected]


 

Suggested Articles

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.